Health & Biotech

Dr Boreham’s Crucible: Expectations are high as Heramed waits to pop in the US

21 hours agoJune 16, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Medical Developments is finding ways to gain without US pain

June 10, 2019June 9, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Can Invitrocue eek out a piece of a $185m ‘humanised mice’ market?

June 3, 2019June 2, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: A lump or two, but Oncosil’s sure it has something good brewing

May 27, 2019May 26, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Which imaging outfit is better value – Pro Medicus or Mach7?

May 20, 2019May 26, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Rhythm Biosciences is ready to trial its hands-off poo test

May 13, 2019June 5, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Is Cynata Therapeutics’ Fujifilm partnership all puff and no blow?

May 6, 2019June 5, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Sienna’s first acquisition opens up the field of play

April 29, 2019April 28, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Are China and the US finally waking up to Compumedics?

April 23, 2019April 22, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Does Osprey Medical’s GPO deal mean the cheque is in the US mail?

April 15, 2019April 14, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: You can get BV any old how, but Starpharma’s here to help

April 8, 2019April 7, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Immutep’s booked itself in for several shots in 2019

April 1, 2019March 31, 2019 | Tim Boreham